Insiders Bristol-Myers Squibb Company Swiss Exchange

Equities

BMY

US1101221083

Market Closed - Swiss Exchange Other stock markets 11:35:20 2019-06-28 am EDT			5-day change	1st Jan Change
44.39 ^CHF	-0.25%		-18.16%	-18.16%

Jul. 12	UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating	MT
Jul. 11	Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors	Jul. 02	CI
Bristol Myers: ex-CEO of Agilent joins Board of Directors	Jun. 19	CF
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	Jun. 18	CI
Germany's Evotec appoints Christian Wojczewski as CEO	Apr. 23	RE
Novartis Nominates Former Bristol Myers Squibb CEO as New Chair	Apr. 23	MT
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand	Apr. 23	MT
Bristol-Myers Squibb Company Announces Gerald Storch Not to Stand for Re-Election to the Board	Mar. 18	CI
Arvinas Appoints Noah Berkowitz as Chief Medical Officer	Mar. 18	MT
Aurora Cannabis Names Simona King CFO; Completes Share Consolidation	Feb. 20	MT
Bristol-Myers Squibb Company Announces Management Changes	Feb. 15	CI
Lonza chairman to step down, drugmaker confirms targets, shares soar	Jan. 26	RE
Evotec says it promptly reported share trades withheld by former CEO	Jan. 22	RE
Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology	Jan. 09	MT
Avacta taps biopharma veteran as Therapeutics business chief	Dec. 19	AN
UniCredit seeks new chair candidate by early 2024, sources say	Dec. 06	RE
UniCredit seeks new presidential candidate by early 2024 - sources	Dec. 06	RE
UniCredit seeks new chair candidate by early 2024, sources say	Dec. 05	RE
Bristol Myers Squibb Insider Bought Shares Worth $150,049, According to a Recent SEC Filing	Dec. 01	MT
Bristol Myers Squibb Insider Bought Shares Worth $423,385, According to a Recent SEC Filing	Nov. 22	MT
Bristol-Myers Squibb Names Christopher Boerner as Chair	Nov. 01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST